Anna Trask - 25 Feb 2022 Form 4 Insider Report for Decibel Therapeutics, Inc.

Reporting relationship: Chief Human Resources Officer
Issuer ticker: N/A
Reported as of: 25 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2022, 15:38:06 UTC
Prior SEC filing: 04 Jan 2022
Next SEC filing: 30 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Elisabeth Leiderman, Attorney-in-Fact

Key filing fact

Anna Trask filed Form 4 for Decibel Therapeutics, Inc. on 28 Feb 2022.

Key facts

This page summarizes Anna Trask's Form 4 filing for Decibel Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2022, 15:38.

Change

Previous filing in this sequence was filed on 04 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DBTX transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +52,500
Change %
Price: $0.000000
Shares after: 52,500
Date: 25 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 52,500
Exercise price: $3.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on February 25, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 25, 2023 and with respect to the remainder in 36 equal monthly installments thereafter through February 25, 2026.

SEC remarks

Chief Human Resources Officer